Literature DB >> 7590828

Genes coding for tumor antigens recognized by cytolytic T lymphocytes.

A Van Pel1, P van der Bruggen, P G Coulie, V G Brichard, B Lethé, B van den Eynde, C Uyttenhove, J C Renauld, T Boon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7590828     DOI： 10.1111/j.1600-065x.1995.tb00084.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN： 0105-2896            Impact factor:   12.988


× No keyword cloud information.
  32 in total

Review 1.  T-cell recognition of self peptides as tumor rejection antigens.

Authors:  Y Kawakami; S A Rosenberg
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

Review 2.  The new vaccines: building viruses that elicit antitumor immunity.

Authors:  N P Restifo
Journal:  Curr Opin Immunol       Date:  1996-10       Impact factor: 7.486

Review 3.  Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens.

Authors:  P Romero
Journal:  Springer Semin Immunopathol       Date:  1996

4.  Overcoming obstacles to the effective immunotherapy of human cancer.

Authors:  Steven A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-27       Impact factor: 11.205

5.  Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.

Authors:  S A Rosenberg; Y Zhai; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; C A Seipp; J H Einhorn; B Roberts; D E White
Journal:  J Natl Cancer Inst       Date:  1998-12-16       Impact factor: 13.506

Review 6.  Immunotherapy III: Combinatorial molecular immunotherapy--a synthesis and suggestions.

Authors:  R G Vile; H Chong
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

7.  An autologous oral DNA vaccine protects against murine melanoma.

Authors:  R Xiang; H N Lode; T H Chao; J M Ruehlmann; C S Dolman; F Rodriguez; J L Whitton; W W Overwijk; N P Restifo; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

Review 8.  The dawn of vaccines for cancer prevention.

Authors:  Olivera J Finn
Journal:  Nat Rev Immunol       Date:  2017-12-27       Impact factor: 53.106

9.  Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells.

Authors:  R Halaban; E Cheng; Y Zhang; G Moellmann; D Hanlon; M Michalak; V Setaluri; D N Hebert
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

Review 10.  Prospects and challenges of building a cancer vaccine targeting telomerase.

Authors:  Robert H Vonderheide
Journal:  Biochimie       Date:  2007-07-17       Impact factor: 4.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.